Understanding the cause of elevated IOP in patients with uveitis is the basis for developing a rational treatment plan.
Cheryl Guttman Krader
As outgoing president of the ASCRS, Edward J. Holland, MD, can be recognized for a number of accomplishments and the introduction of several new initiatives.
Many agents have been investigated in clinical trials for neuroprotection in glaucoma, but none has proven efficacy, and so IOP control continues to be the mainstay strategy for preventing glaucoma progression.
Results from randomized controlled clinical trials investigating populations covering the spectrum from ocular hypertension to advanced glaucoma provide clear evidence that for most patients, glaucoma is an IOP-sensitive optic neuropathy for which lowering IOP is effective in slowing or arresting progression.
The world of glaucoma management in 2012 is feeling the impact of not only a variety of challenges, but also new opportunities.
'High-definition ocular coherence tomography update adds age-related macular degeneration, glaucoma tools
New software (version 6.0) introduced for a proprietary high-definition ocular coherence tomography platform provides researchers and clinicians an expanded set of diagnostic tools to use in the evaluation and management of patients with AMD and glaucoma.
On Feb. 13, Merck announced that it received approval from the FDA to market its one-of-a-kind, preservative-free, prostaglandin analog, tafluprost ophthalmic solution 0.0015%, for lowering IOP in patients with open-angle glaucoma or ocular hypertension.
Ophthalmologists using a proprietary confocal scanning laser ophthalmoscope with a fundus autofluorescence module can now quantify and track progression of geographic atrophy over time, thanks to the release of new software.
Results from an integrated analysis of data from 12 months of follow-up in the two similarly designed prospective, randomized studies comparing aflibercept and ranibizumab indicate that intravitreal injection of aflibercept every 2 months is safe, predictably effective therapy for neovascular age-related macular degeneration and comparable to monthly ranibizumab 0.5 mg.
Severe halos/glare was the issue most feared most by surgeons implanting diffractive multifocal IOLs, according to a survey.